1 completed, 1 enrolling by invitation, 1 recruiting, 1 withdrawn. 2 Not applicable, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 1, Enrolling by invitation 1 |
| Phase 2 | 1 | Withdrawn 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Group 2 Pulmonary Hypertension: new trials by email Literature Review of Group 2 Pulmonary Hypertension trials Research Report on Group 2 Pulmonary Hypertension
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension JK07 - HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction | Phase 2 | Withdrawn | Salubris Biotherapeutics Inc | 2025-12-15 | 2026-05-15 | |
| Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Combination therapy, Monotherapy - Combined Pre- and Post-capillary Pulmonary Hypertension, CpcPH | Phase 4 | Recruiting | Gachon University Gil Medical Center | 64 | 2025-11-24 | 2026-04-03 |
| Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study) Gradient Denervation System - Group 2 Pulmonary Hypertension, Heart Failure | Not applicable | Enrolling by invitation | Gradient Denervation Technologies | 50 | 2024-02-20 | 2026-09-21 |
| Phosphodiesterase Type 5 Inhibitors in Patients With Group 2 Pulmonary Hypertension tadalafil 20 mg then 40 mg if tolerated - Group 2 Pulmonary Hypertension, CpcPH | Not applicable | Completed | Beni-Suef University | 66 | 2023-03-10 | 2026-08-11 |
Heart Failure (2) · Fibromatosis, Gingival, 2 (1) · Heart Failure, Diastolic (1) · Heart Failure, Systolic (1) · Hypertension, Pulmonary (1)
Cardiovascular Diseases (2) · Heart Diseases (2) · Hypertension (1) · Lung Diseases (1) · Respiratory Tract Diseases (1) · Vascular Diseases (1)
Combined Modality Therapy (1) · Tadalafil (1)
Beni-Suef University (1) · Gachon University Gil Medical Center (1) · Gradient Denervation Technologies (1) · Salubris Biotherapeutics Inc (1)
United States (2) · Egypt (1) · South Korea (1)